Position in MLYS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$271,202
-$728,949 QoQ
Shares Held
10,052
-86.4% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#160
of 224 holders
Holding Since
Mar 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MLYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. MLYS ranks #87 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in MLYS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $271,202 | 10,052 | Shares | Sole | 2026-08-03 | |
| 2025-06-30 | $1,000,151 | 73,921 | Shares | Sole | 2025-08-13 | |
| 2023-12-31 | $481,350 | 55,971 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $145,075 | 15,255 | Shares | Sole | 2023-11-21 | |
| 2023-03-31 | $407,097 | 25,996 | Shares | Sole | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||